Behind the scenes: why we created ‘The participation equation’
November 28, 2025 | Insights, Patient first, The participation equation, clinical trials, patient engagement
Go behind the scenes of The participation equation – our call to put people, not just data, at the heart of clinical research.
A call to better understand the human side of research
Clinical trials have never been more advanced – or more complex. With decentralised designs, digital tools, and new recruitment models reshaping the research landscape, one crucial element risks being lost: the human experience.
That’s why we wrote The participation equation. Developed in collaboration with the International Society for Patient Engagement Professionals (ISPEP), the report explores what truly drives people to join, stay in, and complete clinical trials. It’s about understanding participation not as a statistic, but as a story.
And at its heart, the project seeks to answer a simple but profound question – how can we make clinical research as meaningful for participants as it is for science?
The questions that started it all
Every good piece of research begins with curiosity. For us, the spark was an unanswered question.
As science and technology advance, what do trial participants really want and need from their experience?
To find out, we spoke directly to those who know best – the participants themselves. Through surveys with 700 people who have taken part in clinical research across the globe, in-depth interviews with 20 trial participants, and workshops with leading sponsors and researchers, we set out to uncover the lived realities of modern trial participation.
We wanted to go beyond recruitment numbers and retention rates to understand how participants feel – their motivations, frustrations, and triumphs. Because participation is not just a procedural act, it’s an emotional one.
An evolving research landscape
Clinical research is changing rapidly. Hybrid and decentralised models are creating new opportunities for flexibility but also introducing new challenges. While trial designs become more sophisticated, participant experiences don’t always keep pace.
As our findings show, the gap between protocol intent and lived experience can sometimes undermine engagement. People may feel lost in logistics, burdened by travel, or frustrated by unclear communication. Yet when preferences are understood and acted upon, the benefits are measurable: higher completion rates, better data quality, and stronger trust between sponsors and participants.
Patient preference, then, isn’t just feedback, but evidence. Evidence that can help us design trials that are not only scientifically robust but also genuinely patient ready.
The power of collaboration
The participation equation was only possible thanks to collaboration between patients, sponsors, and organisations committed to transforming engagement.
Working with ISPEP and dozens of industry leaders from companies such as AstraZeneca, GSK, and Novartis, we were able to gather a truly 360-degree view of today’s trial experience. Each partner brought a vital perspective – patients shared what matters most, and industry voices explored how to make that insight actionable.
The result is a unique combination of quantitative data and qualitative depth, a conversation between science and empathy.
Why human factors matter
Behind every datapoint is a person. Someone juggling treatment schedules, family life, and uncertainty. Through the research, we heard stories of participants travelling hours each way for clinic visits or feeling anxious about data diaries and digital demands.
These insights revealed a powerful truth. Engagement is emotional. Feeling valued, supported, and informed can make the difference between dropping out and staying the course. Even small gestures, like personalised updates or thank-you notes, can build connection and trust.
Understanding these human factors isn’t a ‘nice-to-have’. It’s central to improving recruitment, retention, and data integrity. Most importantly, it ensures research honours the people who make it possible.
Looking ahead
The participation equation is both a reflection and a call to action.
It shows that when we operationalise patient preferences, and when we treat people as partners rather than participants, we move closer to a future where every trial is designed with humanity at its core.
At Cuttsy+Cuttsy, this is the work we live for – turning insight into action, and data into difference. Because when we listen to what matters to people, we don’t just make research better, we make it meaningful.
Ready to dive deeper? Download The participation equation to explore the full findings, insights, and actionable recommendations.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
A month of insights: Key takeaways from May’s conferences
Explore key insights from some of May’s top healthcare conferences, covering patient engagement, health equity, co-creation, and tech innovation shaping clinical trials.
Cuttsy+Cuttsy and ISPEP highlight key patient insights in new clinical trials report
Explore how Cuttsy+Cuttsy and ISPEP are spotlighting patient engagement in clinical trials through a new global report.
Motivations that matter: Understanding clinical trial participation to create better research
Understanding why people join clinical trials is essential to improving recruitment and designing better research. Explores the diverse motivations driving participation — from altruism and hope for better health to...
Cuttsy+Cuttsy welcomes new team members and celebrates a familiar face returning
Cuttsy+Cuttsy proudly announces the expansion of its team with the addition of three new hires—Michelle, Jay, and Emily—and the welcome return of former team member Sally as Account Director.
AI and away we go: key insights from Reuters Pharma 2025
AI is revolutionising the pharmaceutical industry, as highlighted at Reuters Pharma 2025, with transformative applications across marketing, drug discovery, and patient engagement, despite challenges in adoption, regulation, and data trust.
Exciting updates from our content and strategy team
Cuttsy+Cuttsy celebrates new beginnings with the appointment of Oli Bailey as Strategy Director and recognises team excellence through several well-deserved promotions.
How is generative AI transforming clinical trials?
Discover how generative AI is revolutionising clinical trials, from enhancing patient recruitment to improving data analysis.
Content for all – how to connect with neurodiverse audiences
Discover essential strategies for crafting inclusive and accessible written content tailored for neurodivergent readers.
Cuttsy+Cuttsy launches ccura: AI powered, always human
Cuttsy+Cuttsy introduces ccura, an AI-powered healthcare communications platform that blends technology with human expertise to enhance collaboration, streamline workflows, and deliver patient-focused, high-quality solutions with security and compliance at its...
Two Sides of the Same Coin: Patient Engagement vs Patient Involvement
Unpack the difference between patient engagement and patient involvement.